Product Images Gabapentin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Gabapentin NDC 70518-1544 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Remedy_Label - Remedy Label
Gabapentin is a medicine in the form of 100mg Capsules, with 30 Capsules per package. These capsules are RX ONLY, and the user should keep them out of reach of children. The drug contains instructions for use on the package insert, and should be stored between 20-25°C (88-77°F). The package was provided by Aurobindo Pharma and repackaged by RemedyRepack Inc. The expiration date and lot number are not available. The NDC number for the source is 658562-0198-01.*
Formula - gabapentin fig1
This text appears to provide a formula for calculating "Lt" based on a patient's age and weight, and their creatinine level. However, it is not clear what "Lt" represents or what the purpose of the calculation is. It is possible that additional context or information is needed in order to fully understand the meaning and usefulness of this text.*
Figure 1 - gabapentin fig2
This appears to be a graphical representation chart with a title of "Mean Pain Score". The chart shows a horizontal axis labelled "Weeks" and a vertical axis labelled "Mean Pain Score" with values ranging from 0 to 10. The chart also includes two lines labelled "Placebo" and "Gabapentin, 3600 mg/day" respectively. The chart contains a table with several columns labelled "Baseline", "1", "2", "3", "4", "5", "6", "7", and "8". The text seems to be related to some kind of pain study involving the use of Gabapentin as a treatment.*
Figure 2 - gabapentin fig3
The text is describing a chart or a graph showing the mean pain score at different stages of a dose period. It mentions a 3-week dose period, and a 4-week fixed dose period, with three different treatment options: placebo, 1800 mg/day Gabapentin, and 2400 mg/day Gabapentin. The chart likely includes a baseline measurement.*
Figure 3 - gabapentin fig4
The text describes the results of controlled studies for the treatment of PHN (post-herpetic neuralgia) pain. The studies showed the proportion of responders (patients with more than 50% pain reduction) at the endpoint. The results of Study 1 and Study 2 are presented in Figure 3. The text also includes statistical significance indicators (#p<001 and 5D<0.001) and dosage information (PBO, GBP 3600, GBP 1800, and GBP 2400).*
Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - gabapentin fig5
Chemical Structure - gabapentin str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.